Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon

Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.

05/14/2026, 6:22 AM • Investing

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle Biosciences announced results from the largest prospective multicenter study of its DecisionDx-Melanoma i31-SLNB test, presented at SSO 2026. The study of 912 patients found that patients predicted to have less than 5% risk of sentinel lymph node positivity had an actual positivity rate of 2.6%, with only 1.4% in T1b-T2a tumors. Low-risk patients demonstrated 97.8% three-year recurrence-free survival, supporting the test's ability to identify patients who may safely forgo sentinel lymph node biopsy.

03/09/2026, 7:00 AM • GlobeNewswire

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Castle Biosciences published a prospective validation study in the Journal of the American Academy of Dermatology showing that its AdvanceAD-Tx gene expression profile test can identify patients with moderate-to-severe atopic dermatitis who are significantly more likely to achieve faster and deeper clinical responses with JAK inhibitor therapy. Approximately 30% of patients studied had a JAK Inhibitor Responder Profile and were 5.5 times more likely to achieve EASI-90 improvement by three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%). The test launched in limited commercial access in late 2025.

02/19/2026, 5:46 PM • GlobeNewswire

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

A systematic review and meta-analysis demonstrates that TissueCypher® Barrett's Esophagus test can more accurately identify patients at risk of developing esophageal cancer compared to traditional pathology methods.

12/12/2025, 7:00 AM • GlobeNewswire

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle Biosciences has been named a Houston Top Workplace for the fifth consecutive year, earning recognition for employee culture, including awards in Employee Appreciation, Employee Well-Being, and Professional Development.

11/17/2025, 7:00 AM • GlobeNewswire

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Castle Biosciences announced its Q3 2025 financial results and launched AdvanceAD-Tx, a genetic expression test to help guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis aged 12 and older.

11/11/2025, 7:00 AM • GlobeNewswire

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle Biosciences presented research demonstrating its TissueCypher test can provide advanced risk insights for Barrett's esophagus patients, potentially helping clinicians identify and intervene earlier for patients at higher risk of esophageal cancer progression.

10/26/2025, 3:05 PM • GlobeNewswire

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Castle Biosciences will release its Q3 2025 financial results on November 3, 2025, after market close, with a conference call and webcast to discuss the results at 4:30 p.m. Eastern time.

10/13/2025, 7:00 AM • GlobeNewswire

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

Castle Biosciences was named to Newsweek's inaugural 2025 America's Greatest Companies list, highlighting the company's strong performance in financial strength, workforce dedication, innovation, and corporate sustainability.

09/17/2025, 7:00 AM • GlobeNewswire

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

A study revealed that TissueCypher can identify 15% of non-dysplastic Barrett's esophagus patients with high progression risk to esophageal cancer, potentially enabling more personalized surveillance and treatment strategies.

09/09/2025, 7:00 AM • GlobeNewswire

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.

08/28/2025, 10:44 AM • Benzinga

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Castle Biosciences announced its CEO Derek Maetzold was named a 2025 Most Admired CEO by the Houston Business Journal and received FDA Breakthrough Device designation for its DecisionDx-Melanoma test.

07/29/2025, 7:00 AM • GlobeNewswire

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Castle Biosciences' CEO Derek Maetzold was honored by the Houston Business Journal as a 2025 Most Admired CEO, recognizing his leadership in developing innovative diagnostic tests for various medical conditions.

07/25/2025, 7:00 AM • GlobeNewswire

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle Biosciences announced its DecisionDx-Melanoma test received FDA Breakthrough Device designation, highlighting the test's potential to improve melanoma patient outcomes through personalized risk stratification and prediction of lymph node positivity.

07/23/2025, 7:00 AM • GlobeNewswire

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle Biosciences received multiple Top Workplaces awards in 2025, including national Healthcare Industry and Arizona Top Workplaces recognitions, along with five Culture Excellence awards highlighting innovation, work-life flexibility, leadership, and company values.

07/17/2025, 7:00 AM • GlobeNewswire